Introduction
Conditionally replicating adenoviruses (CRAds), which selectively replicate in tumor cells by genetic engineering and mediate efficient antitumor effects, are drawing much attention as anticancer virotherapy agents, and various types of CRAds have been developed. 1, 2 Clinical trials using CRAds have already been performed, and superior antitumor effects have been demonstrated in several trials. [3] [4] [5] However, there are a few problems to overcome for successful CRAd-mediated cancer virotherapy. First, infection of CRAds is blocked by neutralizing anti-adenovirus (Ad) antibodies. Almost all types of CRAds, which have been developed so far, are based on species-C Ad serotype-5 (Ad5). High seroprevalence against Ad5 in adults has been reported. 6, 7 Second, Ads originally have strong tropism for the liver, resulting in high levels of liver accumulation of Ads after intravenous administration. Even after local injection into tumors, Ads are disseminated from the injected points, drained into blood circulation and accumulated in the liver. [8] [9] [10] In order to overcome these drawbacks, CRAds have been delivered to target cells in vivo using CRAd-infected mesenchymal stem cells or tumor cells as vector. [11] [12] [13] [14] [15] In this strategy, cells infected with CRAds are termed 'carrier cells' and use of these cells allows the CRAds to bypass the pre-existing anti-Ad antibodies. 11, 15 In addition, use of carrier cells significantly reduces the accumulation of Ad vectors in the liver, because Ad capsid proteins, which are responsible for liver accumulation, are not exposed to the outside of the carrier cells. 12, 14, 15 In the above strategy, the CRAds are inserted into and then allowed to replicate within the carrier cells. However, there are still several questions to be addressed about the mechanism for release of CRAds from carrier cells and infection of target cells with CRAds after administration. A previous study by Hamada et al. 11 demonstrated that CRAd-containing cell fragments derived from the carrier cells were internalized by cytoplasmic processes into the target cells. Internalization of the cell fragments of CRAd-loaded carrier cells is considered to be independent of the primary receptor for Ad5, coxsackievirus and Ad receptor (CAR). However, it remains to be clarified whether carrier cells loaded with a conventional CRAd developed from Ad5 can mediate efficient antitumor effects on CAR-negative tumors. CAR-negative tumor cells are an important target because CAR is often downregulated in malignant cancer cells. 16 In the present study, in order to examine the antitumor effects of CRAd-loaded carrier cells on CAR-positive and -negative cells, CRAd-loaded carrier cells were prepared by infection with a conventional CRAd composed of Ad5 or a fiber-substituted CRAd in which fiber proteins are substituted with those of Ad serotype-35 (Ad35) (CRAd-F35). Species-B Ads, including Ad serotypes 3, 11 and 35, recognize human CD46 as a receptor, 17, 18 leading to efficient infection of CAR-negative cells with CRAd-F35. Carrier cells loaded with CRAd-F35 showed efficient antitumor effects on not only CAR-positive tumor cells but also CAR-negative tumor cells, although carrier cells infected with a conventional CRAd showed efficient lysis of only CAR-positive cells.
Materials and methods

Cells
Cells of the human bladder cancer cell lines KK47 and T24 were cultured in RPMI1640 medium containing 10% fetal bovine serum and antibiotics. A549 cells (a human lung adenocarcinoma epithelial cell line) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics.
Preparation of CRAds and carrier cells
A conventional CRAd and a fiber-substituted CRAd containing the midkine promoter for E1 gene expression were constructed as follows: vector plasmids for the CRAds were produced by an improved in vitro ligation method. [19] [20] [21] Briefly, pShuttle2-PL/hMKpro þ E1A-E1B, 22 which possesses the E1A and E1B gene under the control of the midkine promoter, 23 was digested with I-CeuI/PI-SceI and ligated with the I-CeuI/PI-SceIdigested pAdHM3. 20 The resulting plasmid, pAdHM3-hMKpro, was transfected into 293 cells using the Superfect transfection reagent after digestion with PacI in order to generate a conventional CRAd based on Ad5 (CRAd-F5). A vector plasmid for a fiber-substituted CRAd containing the fiber protein of Ad35 (CRAd-F35), pAdHM34-E3( þ ) was constructed by homologous recombination between pAdHM34 24 and the Ad genome fragment encoding E3 genes. pAdHM34 is an Ad vector plasmid encoding the fiber protein of Ad35. The I-CeuI/ PI-SceI-digested pShuttle2-PL/hMKpro þ E1A-E1B was ligated with the I-CeuI/PI-SceI-digested pAdHM34-E3( þ ), resulting in pAdHM34-hMKpro. To produce CRAd-F35, pAdHM34-hMKpro was digested with PacI and transfected into 293 cells as described above. Amplification, purification and determination of virus particle titers of the CRAds were performed as described previously. 25 Carrier cells infected with the CRAds were prepared as follows: A549 cells were infected with CRAd-F5 at 4000 vector particles/cell for 3 h, creating Carrier-F5. Carrier-F35 was similarly prepared by infection with CARd-F35 at 800 vector particles/cell. After a 30-h incubation, the cells were recovered, washed and resuspended in a preservation solution composed of Albuminar (Nippon Boehringer Ingelheim, Tokyo, Japan) and glycerol at a final titer of 2.5 Â 10 7 cells ml
À1
. The carrier cells were radiated at 400 Gy and stored in liquid nitrogen. Infectious titers of carrier cells infected with the CRAds were determined as follows: the carrier cells were frozen and thawed three times. After centrifugation, the supernatants were added to 293 cells for determination of infectious titer using an Adeno-X Rapid titer kit (Clontech, Mountain View, CA). A green fluorescence protein (GFP)-expressing Ad vector based on Ad5, Ad5-GFP, and an Ad vector possessing the fiber protein of Ad35, AdF35-GFP, were prepared in the previous study. 24, 26 Expression levels of CAR and CD46 KK47 cells and T24 cells were incubated with a mouse anti-human CAR monoclonal antibody (Upstate Biotechnology, Temecula, CA) for 1 h at 4 1C Subsequently, the cells were washed, resuspended and incubated with a phycoerythrin-labeled anti-mouse IgG antibody for 1 h at 4 1C (BD Biosciences, San Diego, CA). After washing, the expression levels of CAR were analyzed by flow cytometry with an LSR II flow cytometer, using the FACSDiva software (BD Biosciences). For analysis of human CD46, a fluorescence isothiocyanate-labeled antihuman CD46 antibody (E4.3; BD Biosciences) was used.
In vitro transduction with carrier cells infected with CRAds
For evaluation of in vitro transduction efficiencies of Ad5-GFP and Ad35-GFP, KK47 cells and T24 cells were seeded into a 12-well plate at 1 Â 10 5 cells per well. The next day, the cells were transduced with Ad5-GFP or AdF35-GFP at a multiplicity of infection (MOI) of 100 for 1.5 h. After a 24-h incubation, the GFP expression levels were determined using an LSR II flow cytometer and the FACSDiva software (BD Biosciences).
For evaluation of in vitro antitumor effects of Carrier-F5 and Carrier-F35, the KK47 cells and T24 cells were seeded as described above. The next day, the cells were transduced with carrier cells loaded with the CRAds at an MOI of 200 for 1.5 h. After a total of 72 h of incubation, the viability of the tumor cells was evaluated by Alamar blue assay. For evaluation of antitumor effects of the carrier cells in the presence of anti-Ad serum, the carrier cells were incubated with anti-Ad5 serum for 20 min. Subsequently, the tumor cells were transduced with the carrier cells and antitumor effects were determined by Alamar blue assay. The anti-Ad5 serum was prepared from the blood of mice, which received repeated intraperitoneal injections of a conventional replication-incompetent Ad5 vector expressing b-galactosidase, Ad5LacZ. 27 In order to examine whether cellular attachment of the carrier cells is receptor-dependent, T24 cells were seeded into a 12-well plate at 1 Â 10 5 cells per well. On the following day, T24 cells were pre-incubated with an antihuman CD46 antibody (5 mg ml 
Statistical analysis
Statistical significance was determined by t-test for direct two-group comparisons. Statistical significance was set at Po0.05.
Results
Surface expression levels of CAR and CD46 on human bladder tumor cells In order to examine the surface expression levels of CAR and CD46, which are the primary receptors for Ad5 and Ad35, respectively, on human bladder tumor cells, flowcytometric analysis was performed. KK47 cells showed very-high-level expression of CAR ( Figure 1a) ; in fact, approximately 100% of KK47 cells expressed CAR. On the other hand, more than 99% of T24 cells were CARnegative. CD46 was highly expressed on both KK47 cells and T24 cells (Figure 1b ). There was no significant difference between the expression levels of CD46 on KK47 cells and T24 cells.
In vitro transduction efficiencies of Ad vectors
To examine the transduction efficiencies of Ad vectors in KK47 and T24 cells, both cell lines were transduced with Ad5-GFP and AdF35-GFP at an MOI of 100 for 1.5 h. As shown in Figure 2 , flow-cytometric analysis demonstrated that more than 85% and 95% of KK47 cells expressed GFP after transduction with Ad5-GFP and AdF35-GFP, respectively, owing to the high levels of CAR and CD46 of expression. On the other hand, T24 cells were refractory to Ad5-GFP (only 25.6% were GFPpositive). AdF35-GFP efficiently mediated GFP expression in T24 cells (98.7% were GFP-positive). These GFP expression profiles were well correlated with the expression levels of CD46 and CAR on the cells shown in Figure 1 .
In vitro antitumor effects of carrier cells loaded with CRAds Next, to examine the tumor cell lysis activity of the carrier cells loaded with CRAd-F5 (Carrier-F5) or CRAd-F35 (Figure 3a) . The tumor cell lysis activities of Carrier-F5 and Carrier-F35 were comparable to those of CRAd-F5 and CRAd-F35. High levels of the tumor cell lysis against KK47 cells were also found for Carrier-F5 even after pre-incubation with anti-Ad5 serum, although the anti-Ad5 serum dramatically reduced the tumor cell lysis activities of CRAd-F5 and CRAd-F35. Pre-incubation of Carrire-F35 with anti-Ad5 serum slightly, but significantly, reduced tumor cell lysis activity in KK47 cells.
On the other hand, T24 cells, which are CAR-negative, were almost refractory to Carrier-F5 and CRAd-F5 ( Figure 3b) ; however, Carrier-F35 and CRAd-F35 mediated less than 20% cell survival for T24 cells because T24 cells highly expressed CD46, as shown in Figure 1 . Anti-Ad5 serum apparently blocked the tumor cell lysis activity of CRAd-F35 against T24 cells; however, a significant reduction in the lysis of T24 cells was not found for Carrier-F35. These results indicate that Carrier-F35 mediates efficient tumor cell lysis for CAR-negative tumor cells as well as CAR-positive tumor cells.
Cellular attachment of Carrier-F35 in a CD46-independent manner To examine whether attachment of Carrier-F35 to the cell surface is independent of CD46, T24 cells were preincubated with a monoclonal anti-human CD46 antibody, MEM-258, and subsequently infected with Carrier-F35 or CRAd-F35. We previously demonstrated that the antihuman CD46 antibody MEM-258 significantly inhibits the binding of Ad35 fiber knob to human CD46. 29 Cellular attachment of CRAd-F35 was significantly inhibited by the anti-CD46 antibody, indicating that CRAd-F35 infects cells in a CD46-dependent manner (Figure 4 ). On the other hand, significant reduction in the cellular attachment of Carrier-F35 was not found in the presence of the anti-CD46 antibody. This result indicates that Carrier-F35 binds to the cells in a CD46-independent manner.
In vivo antitumor effects of carrier cells loaded with CRAds Next, to evaluate the in vivo antitumor effects of Carrier-F5 and Carrier-F35, Carrier-F5 or Carrier-F35 was intratumorally administered to subcutaneous tumor-bearing mice, and tumor growth was examined. In KK47 tumorbearing mice, similar levels of reduction in tumor growth were found for both Carrier-F5 and Carrier-F35, although statistically significant differences were not found among Carrier-none, Carrier-F5 and Carrier-F35 (Figure 5a ). In T24 tumors, both Carrier-F5 and Carrier-F35 mediated statistically significant reduction in tumor growth, compared with carrier cells, which were not loaded with the CRAd (Carrier-none); however, Carrier-F35 showed a more efficient antitumor effect on T24 
Discussion
The aim of this study was to evaluate the antitumor effects of carrier cells loaded with a conventional CRAd or a fiber-substituted CRAd on CAR-positive and CARnegative tumor cells. For preparation of CRAd-loaded carrier cells, the carrier cells should be efficiently infected with CRAds and support the replication of CRAds. In previous studies of CRAd-loaded carrier cells, mesenchymal stem cells have often been used as carrier cells, and fiber-mutant CRAds have been used for efficient infection of mesenchymal stem cells, leading to efficient preparation of CRAd-loaded carrier cells, because mesenchymal stem cells poorly express CAR, which is the primary receptor for Ad5. 30, 31 Our group has previously demonstrated that human and mouse mesenchymal stem cells are less efficiently transduced with conventional Ad vectors, but that fiber-mutant Ad vectors, including an Ad vector containing the RGD (Arg-Gly-Asp) peptide and the poly-lysine peptide in the HI loop and the C-terminus of the fiber knob, respectively, and a fibersubstituted Ad vector showing the fiber protein of Ad35, efficiently transduce mesenchymal stem cells. 32, 33 Mesenchymal stem cell-based carrier cells loaded with fibermutant CRAds mediate efficient antitumor effects; however, it has remained unclear whether use of a fibermutant or fiber-substituted CRAd is crucial for not only efficient preparation of carrier cells but also efficient killing of CAR-negative tumor cells. In this study, a fibersubstituted CRAd possessing Ad35 fiber proteins (CRAd-F35) was used for preparation of carrier cells. CRAd-F35 binds to human CD46 as an infectious receptor. 17, 18 Human CD46 is upregulated in malignant tumor cells, including CAR-negative tumor cells, 34 leading to efficient infection of CAR-negative cells with CRAd-F35. This study demonstrated that Carrier-F35 mediated efficient lysis of not only CAR-positive tumor cells but also CARnegative tumor cells, although Carrier-F5 failed to efficiently kill CAR-negative tumor cells in vitro. These results indicate that use of a fiber-substituted CRAd is crucial for the antitumor effects of CRAd-loaded carrier cells on CAR-negative tumor cells.
In in vitro infection experiments with carrier cells (Figure 3) , pre-incubation of Carrier-F5 and Carrier-F35 with anti-Ad5 serum mediated efficient antitumor effects The previous study has demonstrated that carrier cells were engulfed by the tumor cells in a receptor-independent manner. 11 However, T24 cells, which expressed low levels of CAR, were almost refractory to Carrier-F5 (Figure 3b ). Even though Carrier-F5 was internalized in T24 cells in a CAR-independent manner, and CRAd-F5 replicated and was released from T24 cells, the CRAd-F5 released from T24 cells could not infect the neighboring tumor cells owing to the absence of CAR. CRAd-F35 released from carrier cells efficiently infects T24 cells owing to high expression of CD46, leading to high levels of tumor cell lysis activity of Carrier-F35. Interaction between the fiber proteins of CRAds and cell-surface receptors is crucial for the antitumor effects of CRAdloaded carrier cells.
Pre-existing anti-Ad antibodies are a major obstacle for not only gene therapy using a replication-incompetent Ad vector but also virotherapy using CRAds. More than 50% of adults have been reported to possess anti-Ad5 antibodies. 35 Sumida et al. 36 demonstrated that neutralizing anti-Ad5 antibodies mainly recognize the hexon protein among Ad5 capsid proteins. The tumor cell lysis activity of both CRAd-F5 and CRAd-F35 was largely reduced by pre-incubation with anti-Ad5 serum, probably because of neutralizing anti-Ad5 antibodies recognizing hexon bound to the hexon of CRAd-F5 and CRAd-F35, leading to inhibition of infection with CRAd-F5 and CRAd-F35. The hexon of CRAd-F35 is derived from Ad5.
In In addition to efficient infection of neighboring CARnegative tumor cells with a fiber-substituted CRAd, intracellular trafficking, including release of CRAds from carrier cells inside the tumor cells, might be enhanced by fiber substitution. Shayakhmetov et al. 40 demonstrated that a fiber-substituted Ad vector containing the Ad35 fiber protein showed an intracellular trafficking pattern different from that of a conventional Ad5 vector. Replication of a chimeric CRAd possessing the fiber knob of Ad serotype-3, which belongs to species-B, was enhanced in multiple steps, including nuclear transport of the virus genome and E1A transcription, compared with a conventional CRAd. 41 In in vivo experiments, Carrier-F5 showed significant reduction in tumor size derived from CAR-negative T24 cells, although much higher reduction in tumor size was found for Carrier-F35. After internalization of Carrier-F5 into T24 cells, CRAd-F5 released from T24 cells would infect the neighboring cells through interaction between av-intergrins and the RGD (Arg-Gly-Asp) motif in the penton base of Ad5, although affinity between av-intergrins and the RGD motif is much lower than that between CAR and the Ad5 fiber knob. Our group previously demonstrated that intra-tumoral injection of a conventional replication-incompetent Ad vector resulted in a certain level of transgene expression in CARnegative B16 tumors. 8, 9 In summary, this study demonstrated that carrier cells containing a fiber-substituted CRAd, Carrier-F35, showed efficient antitumor effects in vitro and in vivo on both CAR-positive and CAR-negative tumors. Furthermore, anti-Ad5 serum did not largely prevent the tumor cell lysis activity of Carrier-F5 and Carrier-F35. This approach using carrier cells would enhance the safety and effectiveness of CRAds for cancer virotherapy.
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